- Do you own shares of Optimer Pharmaceuticals, Inc. (NASDAQ GS: OPTR )?
- Did you purchase any of your shares prior to July 30, 2013?
- Do you think the proposed buyout price is too low?
- Do you want to discuss your rights?
Cubist Pharmaceuticals on Tuesday committed up to $1.6 billion to acquire two makers of next-generation antibiotics in a bid to expand aggressively its acute care product portfolio.
Stock futures are little changed Wednesday despite upbeat reports on GDP and jobs ahead of the Fed announcement.
Cubist announces two acquisitions in one day.